ArticleMedicine2025
"Platelet/lymphocyte" and "neutrophil/lymphocyte" ratios in children with rheumatic heart involvement.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine how platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios change in children diagnosed with Acute Rheumatic Fever (ARF) who are followed up in our clinic. Additionally, we aimed to investigate whether these values are useful in predicting the long-term development of chronic rheumatic heart disease in these patients. A total of 27 patients diagnosed with ARF with who were referred to the Pediatric Cardiology outpatient clinic between January 2019 and August 2023 were included in this study. The retrospective records of the patients were reviewed. Twenty-seven ARF patients (14 females, 13 males; mean age 10.3 ± 2.3 years) and 27 controls (12 females, 15 males; mean age 8.9 ± 3.2 years) were evaluated. Carditis was present in 85.2% of ARF cases at diagnosis, with mitral regurgitation being the most common lesion (29.6%). Leukocyte count, PLR, and NLR were significantly elevated in the ARF group compared to controls (P = .04, .001, .014), while lymphocyte counts were reduced (P = .001). Severe valve involvement was associated with lower PLR (P = .022), but not with NLR (P = .12). Although ARF incidence is declining in developed countries, it remains a significant health issue in developing regions. Consistent with global data, carditis - especially mitral regurgitation - was the predominant finding in our cohort. NLR and PLR have emerged as stable markers for cardiovascular risk, unaffected by exercise or dehydration. Our results demonstrate increased leukocyte counts, NLR, and PLR alongside decreased lymphocytes in ARF patients. Importantly, lower PLR correlated with more severe valve disease, unlike NLR. These findings highlight PLR's potential as a prognostic biomarker, meriting further research in larger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.